Tezosentan

Last updated
Tezosentan
Tezosentan.png
Tezosentan molecule spacefill.png
Clinical data
ATC code
  • none
Identifiers
  • N-[6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-propan-2-ylpyridine-2-sulfonamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C27H27N9O6S
Molar mass 605.63 g·mol−1
3D model (JSmol)
  • O=S(=O)(c1ncc(cc1)C(C)C)Nc3nc(nc(OCCO)c3Oc2ccccc2OC)c5ccnc(c4n[nH]nn4)c5
  • InChI=1S/C27H27N9O6S/c1-16(2)18-8-9-22(29-15-18)43(38,39)34-26-23(42-21-7-5-4-6-20(21)40-3)27(41-13-12-37)31-24(30-26)17-10-11-28-19(14-17)25-32-35-36-33-25/h4-11,14-16,37H,12-13H2,1-3H3,(H,30,31,34)(H,32,33,35,36) Yes check.svgY
  • Key:TUYWTLTWNJOZNY-UHFFFAOYSA-N Yes check.svgY
   (verify)

Tezosentan is a non-selective ETA and ETB receptor antagonist. [1] It acts as a vasodilator and was designed by Actelion as a therapy for patients with acute heart failure. However, studies showed that tezosentan did not improve dyspnea or reduce the risk of fatal or nonfatal cardiovascular events. [2]

References

  1. ↑ Urbanowicz W, Sogni P, Moreau R, Tazi KA, Barriere E, Poirel O, et al. (December 2004). "Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats". Gut. 53 (12). BMJ Publishing Group Ltd & British Society of Gastroenterology: 1844–9. doi:10.1136/gut.2003.036517. PMC   1774327 . PMID   15542526.
  2. ↑ "Tezosentan does not appear to improve symptoms for patients with acute heart failure". Medical Studies/Trials. news-medical.net. 7 Nov 2007. Retrieved 2007-11-24.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.